| | Democratic Republic of Congo has started using the experimental mAb114 Ebola treatment on patients in the east of the country, the health ministry said on Tuesday, the first time it has been deployed against an active outbreak. | |
| China's Ministry of Agriculture reported on Tuesday an outbreak of foot and mouth disease in its central province of Henan | |
| Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker. | |
| (Reuters Health) - The vapor from e-cigarettes may boost the production of inflammatory chemicals in the lungs, while disabling key cellular defenders against infection, a new study suggests. | |
| (Reuters Health) - For decades, doctors have told parents to talk to kids as often as possible to help build speech and language skills. Now, a new study suggests that how parents talk to children may matter just as much as how much time they spend talking. | |
| Many U.S. doctors don't discuss the harms of lung cancer screening or the potential for overdiagnosis in conversations with current and former smokers about whether tests are necessary, two new studies suggest. | |
| (Reuters Health) - State laws designed to increase teen vaccination against the cancer-causing human papillomavirus (HPV) don't appear to influence adolescents' choices about whether to become sexually active or use condoms, a U.S. study suggests. | |
| (Reuters Health) - When it comes to childhood obesity, sedentary behavior may be the most influential and controllable factor that parents can change, especially through managing screen time, according to a new American Heart Association Science Advisory. | |
| Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States. | |
| Anglo-American biotech company Orchard Therapeutics has raised a further $150 million to fund its work in gene therapy, building on earlier fundraisings worth more than $140 million. | |
| A Californian court finding that a Monsanto weedkiller caused cancer in a school groundskeeper sent shares in an Australian maker of a similar product, Nufarm Ltd, tumbling almost 17 percent to a more than two-year low on Monday. | |
|
| |